Navigation Links
NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
Date:6/10/2008

IV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the Company believes offers significant advantages over other pain therapies. NeurogesX' marketing authorization application (MAA) to the European Medicines Agency (EMEA) was accepted for review in September 2007 and NeurogesX plans to file a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) in 2008 for PHN.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the expected benefits of NeurogesX' lead product candidate, NGX-4010. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, NeurogesX' product candidate may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; physician or patient reluctance to use NGX-4010, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in clinical development, obtaining regulatory approval, market acceptance and commercialization of NGX-4010 and the advantages of NGX-4010 over other pain therapies. For further information regarding these and other risks rel
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
2. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
3. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
4. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
5. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
6. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
7. ASPIRE Independent Review Board Announces 10 Ways to Protect Participants Rights in Clinical Drug Trials and Optimize Results From Research
8. Atrium Medical Corporation Announces First Implant of First-in-Man CINATRA(TM) Voclosporin Coated Coronary Stent
9. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
10. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
11. Anpath Group, Inc. Announces Addition of MRSA and VRE Claims for Its EnviroTru(R) Disinfectant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... RMD ) today announced results for its fourth ... Revenue for the quarter was $415.2 million, flat compared to ... on a constant currency basis). Net income was $87.7 million, ... June 30, 2013. Diluted earnings per share for the quarter ... quarter ended June 30, 2013.  The results ...
(Date:7/31/2014)... (the "Company") (Nasdaq: PCYC ) today reported financial ... 2014. Financial Results for the Six Months and ... the quarter ended June 30, 2014 increased to $113.0 million ... primarily due to IMBRUVICA ® (ibrutinib) net product revenue ... six months ended June 30, 2014 increased to $232.4 million ...
(Date:7/31/2014)... VIEW, Calif. , July 31, 2014 /PRNewswire/ ... today provided an update on its pipeline and ... 2014, Alexza expects to initiate a Phase 2a ... is being developed for the management of patients ... two new Staccato -based product candidates for ...
Breaking Medicine Technology:RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24
... announces that a new market research report is available ... and Urology Devices Market Outlook to 2017 ... and Urology Devices Market Outlook to 2017 ... America Nephrology and Urology Devices Market Outlook to 2017" ...
... YORK, April 12, 2011 Reportlinker.com announces that ... its catalogue: Gastric Cancer - ... – Volume I 2011 ... Drug Forecasts and Treatment Analysis to 2020 – ...
Cached Medicine Technology:Reportlinker Adds North America Nephrology and Urology Devices Market Outlook to 2017 2Reportlinker Adds North America Nephrology and Urology Devices Market Outlook to 2017 3Reportlinker Adds North America Nephrology and Urology Devices Market Outlook to 2017 4Reportlinker Adds North America Nephrology and Urology Devices Market Outlook to 2017 5Reportlinker Adds North America Nephrology and Urology Devices Market Outlook to 2017 6Reportlinker Adds North America Nephrology and Urology Devices Market Outlook to 2017 7Reportlinker Adds North America Nephrology and Urology Devices Market Outlook to 2017 8Reportlinker Adds North America Nephrology and Urology Devices Market Outlook to 2017 9Reportlinker Adds North America Nephrology and Urology Devices Market Outlook to 2017 10Reportlinker Adds North America Nephrology and Urology Devices Market Outlook to 2017 11Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 2Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 3Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 4Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 5Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 6Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 7Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 8Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 9Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 10Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 11Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 12Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 13Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 14Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 15Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 16Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 17Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 18Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 19Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 20Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 21Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 22
(Date:7/31/2014)... Steven Reinberg HealthDay ... -- Many obese and overweight kids don,t see themselves ... impossible, researchers report. In a new study, 27 ... than 3 percent overestimated it. About 25 percent of ... overestimated it, according to the study. "Efforts to ...
(Date:7/31/2014)... an algorithm aimed to diagnose pediatric patients with ... (CT) scans, without affecting diagnostic accuracy, Mayo Clinic ... recently published in the journal Surgery . ... of acute abdominal pain in children. Appendicitis occurs ... pus. CT scans are often used to diagnose ...
(Date:7/31/2014)... 2014 Joseph M. Lee, M.D., M.S., ... (CDHV), a leading provider of quality cardiovascular and internal ... Dr. Lee is a board certified cardiologist with ... In addition to his position at CDHV, Dr. Lee ... Hospital/ Columbia University Medical Center. Dr. Lee is board ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Millions of ... Some have had traumatic experiences as a child and ... dental work. As a highly experienced NJ cosmetic ... experience anxiety during their dental procedure. To help ... experienced team at Champagne Smiles offer several sedation dentistry ...
(Date:7/31/2014)... The VitalSleep anti snoring device is a mandibular advancement ... a snorers airway to quiet snoring. , Dawn M. of ... with her husband by allowing them to share the same bedroom ... began about 15 years ago and I remember nights when it ... and had to head downstairs for any relief. As the years ...
Breaking Medicine News(10 mins):Health News:1 in 4 U.S. Kids Underestimate Their Weight, Study Finds 2Health News:1 in 4 U.S. Kids Underestimate Their Weight, Study Finds 3Health News:ColumbiaDoctors of the Hudson Valley Welcomes Joseph M. Lee, M.D., M.S., R.P.V.I. 2Health News:ColumbiaDoctors of the Hudson Valley Welcomes Joseph M. Lee, M.D., M.S., R.P.V.I. 3Health News:Champagne Smiles is Thrilled to Now Offer Sedation Dentistry to their Patients 2Health News:New Snoring Mouthpiece Reviews from VitalSleep 2
... THURSDAY, April 5 (HealthDay News) -- More aggressive treatment ... (RA) is among the most important changes recommended in ... change is the result of emerging opinions that RA-related ... helps preserve patients, physical function, quality of life and ...
... economics behind the high U.S. teen birth rates, and ... rate of Massachusetts youth: high income inequality and low ... College economist Phillip B. Levine and University of Maryland ... to study the role that income inequality plays in ...
... at the Johns Hopkins Bloomberg School of Public Health and ... antibiotics previously banned by the U.S. government for poultry production ... March 21 in Environmental Science & Technology . ... Livable Future and ,Arizona State,s Biodesign Institute, looked for drugs ...
... Weill Cornell Medical College announced today the establishment of ... improve health and healthcare through informatics and technology. To ... Health Dr. Nirav R. Shah gave the keynote address. ... collaboration among a team of faculty from multiple departments ...
... 4 (HealthDay News) -- The U.S. Food and Drug Administration ... drug bevacizumab, most commonly known as Avastin, is being sold ... counterfeit product -- which the FDA says contains no active ... a Roche cancer medication that is approved for use in ...
... HealthDay Reporter , WEDNESDAY, April 4 (HealthDay News) ... being passed through generations, could play an important role ... Three research teams sequenced the genes of children with ... families, and compared the sequences with those of their ...
Cached Medicine News:Health News:Treat Rheumatoid Arthritis Early and Aggressively: Guidelines 2Health News:Wellesley study shows income inequality a key factor in high US teen births 2Health News:Researchers find evidence of banned antibiotics in poultry products 2Health News:Researchers find evidence of banned antibiotics in poultry products 3Health News:Weill Cornell Medical College establishes Center for Healthcare Informatics and Policy 2Health News:Weill Cornell Medical College establishes Center for Healthcare Informatics and Policy 3Health News:More Fake Avastin Found in U.S., FDA Says 2Health News:Researchers Find Gene Mutations That May Be a Key to Autism 2Health News:Researchers Find Gene Mutations That May Be a Key to Autism 3Health News:Researchers Find Gene Mutations That May Be a Key to Autism 4
... with the ultimate space efficient engineering ... new Topcon Express Lane the perfect ... practice environments: Ultimate Space EfficiencyComplete, ergonomically ... an 8' X 9' room without ...
... who need to move their imaging system from ... solution. The IMAGEnet Portable System features a rugged ... monitor. This portable PC solution can be coupled ... be tailored to your multi-site imaging needs. The ...
... combines the best 32-bit software package (IMAGEnet ... offerings to bring you a fast reliable ... efficient "mid-resolution" package takes advantage of the ... the latest graphics capture technology and a ...
Inquire...
Medicine Products: